Weight loss Investigational

Peptide YY

A satiety-linked gut hormone that has long been studied in obesity and appetite regulation.

Gut HormoneSatietyObesityInvestigational

Also referenced as: PYY, PYY3-36

Also appears in: Hormone

Public product evidence No certificate records are bound to a tracked Peptide YY product page A record counts here only when a vendor publishes a certificate against one of its own tracked Peptide YY product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Research area
Weight-loss / incretin research

Primary research area: Weight loss. Also surfaces under Hormone for browsing and discovery.

Body systems
Hormones · Gut

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
2

PYY, PYY3-36

Signal depth
Medium

No FDA label signal · 720 trials · 4432 PubMed results

Early
Research evidence

Peptide YY has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.

Peptide YY has 4 name-matched clinical trials (highest phase: Early Phase 1) and 4432 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data
Phase 1
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
Top-tier journals
EARLY_PHASE1 Degradation of the Anorexic Hormone Peptide YY Trial APPETITE: linguAl PYY3-36 on aPpEtite and acuTe Energy InTakE NA · Randomized Protein Dose-repsonse Effect on GLP-1, PYY and Appetite in Male Subjects Nature · 2,351 citations Gut hormone PYY3-36 physiologically inhibits food intake Nature · 2,268 citations Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide New England Journal of Medicine · 1,604 citations Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Evidence history
  1. 2026-11-01 Preclinical → Early Band Preclinical → Early; +22 trials; +3 PubMed
  2. 2026-10-17 Promising → Preclinical Band Promising → Preclinical
  3. 2026-10-15 Preclinical → Promising Band Preclinical → Promising
  4. 2026-10-10 Early → Preclinical Band Early → Preclinical; -7 trials; +2 PubMed
  5. 2026-10-08 Promising → Early Band Promising → Early; +1 PubMed
  6. 2026-10-03 Early → Promising Band Early → Promising; +8 trials
  7. 2026-10-02 Promising → Early Band Promising → Early; +1 PubMed
  8. 2026-09-30 Early → Promising Band Early → Promising; +7 trials
  9. 2026-09-26 Promising → Early Band Promising → Early; -22 trials
  10. 2026-09-22 Preclinical → Promising Band Preclinical → Promising; -8 trials
  11. 2026-09-19 Promising → Preclinical Band Promising → Preclinical; +8 trials; +1 PubMed
  12. 2026-09-18 Early → Promising Band Early → Promising; -8 trials
  13. 2026-09-17 Promising → Early Band Promising → Early; +22 trials; +2 PubMed
  14. 2026-09-16 Early → Promising Band Early → Promising; -22 trials
  15. 2026-09-12 Promising → Early Band Promising → Early; +22 trials; +1 PubMed
  16. 2026-09-11 Preclinical → Promising Band Preclinical → Promising; +2 PubMed

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-02 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What peptide YY is

Peptide YY, often shortened to PYY, is a satiety-linked gut hormone involved in appetite regulation.

Why it matters

PYY belongs in any serious obesity-peptide library because it is part of the physiological foundation behind modern appetite-control pharmacology.

Regulatory context

Peptide YY is not FDA approved as a standard peptide therapy in the United States.

Practical reading note

PYY is one of those peptides that matters scientifically even when later drug development ends up using more stable analogs or combinations instead of the native hormone itself.